On 5 June 2026, ECHA’s Committee for Risk Assessment (RAC) adopted an opinion recommending the harmonised classification of resorcinol as a Category 1 endocrine disruptor for human health (ED HH 1 – EUH380). Published on 11 September[1], the opinion marks RAC’s first...
